In 2008, approximately 11,000 women in the United States will be diagnosed with cervical cancer and more than 3,800 American women will die of this disease. The recent approval by the Food and Drug Administration of a human papillomavirus (HPV) vaccine that is over 90% effective in preventing new infections and precancerous cervical lesions caused by the HPV types that cause cervical cancer may possibly reduce the incidence of cervical cancer. However, a number of unresolved issues exist regarding this vaccine. This paper will explore considerations and challenges facing healthcare educators regarding the HPV vaccine in the following areas: (a) demographic, (b) social, (c) economic, (d) ethical, and (e) political.




Submission Location


To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.